Special Episode: Addition of Valbenazine to Treat Huntington Disease Chorea

Commentary
Podcast

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Erin Furr-Stimming, MD, FAAN, FANA. [LISTEN TIME: 11 minutes]

Erin Furr-Stimming, MD, FAAN, FANA

Erin Furr-Stimming, MD, FAAN, FANA

A special episode of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This episode, "Addition of Valbenazine to Treat Huntington Disease Chorea," features an exclusive interview with Erin Furr-Stimming, MD, FAAN, FANA, a professor of neurology at McGovern Medical School of UTHealth Houston, and principal investigator of the phase 3 KINECT-HD studies. She discussed the recent expanded indication of valbenazine (Ingrezza; Neurocrine Biosciences) to include the treatment of chorea associated with Huntington disease (HD), offering her immediate reaction to the news. In addition, she spoke about the efficacy observed in these trials, the advantages valbenazine has as a VMAT2 inhibitor, and the remaining unmet needs in the management of HD.1

Click here to read more of NeurologyLive's coverage of the valbenazine approval.

EPISODE BREAKDOWN

  • 0:30 – Valbenazine approved for Huntington disease chorea
  • 1:35 – Erin Furr-Stimming, MD, FAAN, FANA, on immediate reaction
  • 2:15 – Treatment toolbox for HD chorea 
  • 3:05 – Furr-Stimming on mechanistic advantages of valbenazine
  • 5:10 – Phase 3 efficacy data of valbenazine
  • 5:55 – Furr-Stimming on greatest clinical takeaways from trials
  • 6:55 – Current state of Huntington management
  • 8:00 – Furr-Stimming on current unmet needs for patients, including research on disease-modifying therapies

Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCE
1. Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease. News Release. Neurocrine Biosciences. Published August 18, 2023. Accessed August 21, 2023.
Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.